Research demonstrates that 5-amino-1MQ administration enhances mitochondrial respiratory capacity through improved NAD+ availability for complex I function and TCA cycle enzymes
In the STEP-1 trial of 1,961 adults (Wilding and colleagues, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021), participants on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight at 68 weeks, compared to 2.4 percent on placebo
99% purity
However, this clinical history does not extend any licensed status to the 10mg lyophilised research format, which is supplied strictly for laboratory investigation only
Before treatment is administered, the treatment area is cleaned to ensure it is free from any impurities or oils
Mechanism of Action & Benefits